Incyte Corporation

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Incyte Corporation sits in the top decile of US sponsors by registered trial count (#137 of 15,742 sponsors by registered trial count).

239 total trials 37 currently recruiting 126 completed early-phase tilt top decile by trial count

Incyte Corporation: 239 sponsored US clinical trials, 37 recruiting.

Incyte Corporation sponsors 239 registered US clinical trials on ClinicalTrials.gov, 37 of them currently recruiting, and 126 completed. 50 of these trials are in Phase 3-4 (later-stage) and 183 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Solid Tumors, with 7 trials.

Top-decile sponsor footprint

Incyte Corporation ranks in the top decile of sponsors by registered trial count (#137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 8/100

126 of 186 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (67.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

239 total, page 3 of 5

TERMINATED Phase 3

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

NCT04551053
TERMINATED Phase 3

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

NCT04551066
COMPLETED Phase 2

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo

NCT04818346
COMPLETED Phase 1

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.

NCT04831996
COMPLETED Phase 1

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.

NCT04831944
TERMINATED Phase 1

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

NCT04272034
COMPLETED Phase 1

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

NCT04580485
COMPLETED Phase 3

Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

NCT04472429
COMPLETED Phase 3

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

NCT04530344
COMPLETED Phase 1

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

NCT04242199
COMPLETED Phase 2

To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

NCT04476043
COMPLETED Phase 1

Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

NCT04370704
TERMINATED Phase 3

Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

NCT04377620
TERMINATED Phase 2

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

NCT04003610
COMPLETED Phase 2

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

NCT04071366
TERMINATED Phase 1

Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation

NCT03978637
TERMINATED Phase 1

Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

NCT03721965
TERMINATED Phase 2

Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

NCT04003623
TERMINATED Phase 2

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

NCT03822117
COMPLETED Phase 3

Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)

NCT04057573
TERMINATED Phase 1

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

NCT03837509
COMPLETED Phase 3

Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)

NCT04052425
TERMINATED Phase 3

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

NCT03656536
COMPLETED Phase 1

A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis

NCT03920852
COMPLETED Phase 2

A Study of INCB050465 in Primary Sjögren's Syndrome

NCT03627065
COMPLETED Phase 2

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

NCT03599713
TERMINATED Phase 2

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT03584516
COMPLETED Phase 2

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

NCT03679767
COMPLETED Phase 3

TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

NCT03745651
COMPLETED Phase 3

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

NCT03745638
COMPLETED Phase 1

A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors

NCT03762447
COMPLETED Phase 1

A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

NCT03688152
COMPLETED Phase 2

A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia

NCT03538041
COMPLETED Phase 2

A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)

NCT03597295
COMPLETED Phase 1

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

NCT03652077
TERMINATED Phase 1

A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

NCT03522142
COMPLETED Phase 1

INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

NCT03589651
COMPLETED Phase 2

A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

NCT03569371
COMPLETED Phase 1

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

NCT03424122
TERMINATED Phase 1

A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma

NCT03514407
TERMINATED Phase 1

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

NCT03347123
COMPLETED Phase 2

A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

NCT03126019
TERMINATED Phase 1

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors

NCT03361228
TERMINATED Phase 1

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

NCT03320642
COMPLETED Phase 2

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

NCT03144687
COMPLETED Phase 2

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

NCT03322566
TERMINATED Phase 3

Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer

NCT03348904
COMPLETED Phase 3

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

NCT03374488
COMPLETED Phase 2

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

NCT03144674
COMPLETED Phase 2

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

NCT03322540
← Previous Page 3 of 5 Next →

Phase Distribution

PhaseTrial count
Phase 1 100
Phase 2 83
Phase 3 49
Phase 4 1

Therapeutic Areas

Solid Tumors 7
Prurigo Nodularis 5
Non-segmental Vitiligo 4
Myeloproliferative Neoplasms 4
Myelofibrosis 4
Chronic Graft Versus Host Disease 4
Atopic Dermatitis 4
Ovarian Cancer 4
Healthy Participants 4
Hidradenitis Suppurativa 4

What is open in the Incyte Corporation pipeline

37 recruiting of 239 indexed (15% open); 126 completed (53%).

Phase mix: 50 late (III/IV) vs 183 early (I/II) (early-phase heavy).

Top condition: Solid Tumors (7 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Incyte Corporation: open-pipeline peers nationwide

Peers matched on 239 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Incyte Corporation sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 10%15%20%25% Total trials Recruiting share Incyte CorporationUniversity of Massachusetts, WorcesterLoma Linda UniversityDaiichi SankyoState University of New York at BuffaloBrigham and Women's HospitalNorthwestern UniversityNationwide Children's HospitalUniversity of Michigan Rogel Cancer Center
Incyte Corporation sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Incyte Corporation sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 239 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Incyte Corporation page

239 registered trials is a research-attention snapshot, not an endorsement of Incyte Corporation or any single study.

  • 37 of Incyte Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Solid Tumors is the condition Incyte Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Solid Tumors trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Incyte Corporation pipeline card: 239 registered trials from official public datasets.Report a data error.